EUVIMEDDescobrir EUVIMED
Open access

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation

Zhenzhen Yin, Simeng Lu, Limeng Wu, Yao Sun, Day Caven Blake, Jie Chen, Lukas D Landegger, William Ho, Bingyu Xiu, Adam P Jones, Alona Muzikansky, Helen A Shih and 3 more

Theranostics · 2026

DOI: 10.7150/thno.123726 ↗

At a glance

Journal article in Theranostics, 2026. Written by Zhenzhen Yin and 14 co-authors. Institution: Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. Major MEDLINE topics: Immune Checkpoint Inhibitors, Cochlea, Neurilemmoma, Membrane Proteins. The full text is freely available in PubMed Central. Funded by: NIDCD NIH HHS, NINDS NIH HHS.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Rationale

NF2-related schwannomatosis (NF2-SWN) is a progressive neurological disorder with a hallmark of bilateral vestibular schwannomas (VSs), leading to irreversible hearing loss and reduced quality of life. To date, the FDA has not approved any pharmacological therapies for treating VS or hearing loss. While radiotherapy (RT) is the standard treatment for growing VSs, it often exacerbates hearing loss. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, their efficacy in non-malignant tumors like VS remains largely unexamined.

Methods

We used immune-competent VS mouse models to assess the efficacy of combined anti-PD1 (αPD1) and RT treatment, tumor growth, and hearing preservation.

Results

We found three significant therapeutic benefits: i) RT induces immunogenic cell death and activates the STING pathway, enhancing αPD1 efficacy and generating long-term immune memory, ii) The combination strategy reduces the required RT dose necessary for effective tumor control, potentially minimizing RT injury to surrounding normal tissues, and iii) RT to peripheral nerve tumor induces a systemic abscopal effect, which enhances αPD-1 efficacy to effectively control intracranial schwannomas without direct irradiation, sparing the cochlea from radiation exposure and avoiding auditory radiation injury.

Conclusion

Our findings provide a compelling rationale for deploying ICIs in combination with radiotherapy as a novel treatment approach for patients with VS and NF2-SWN.

Subjects

MeSH terms (MEDLINE)

Immune Checkpoint InhibitorsCochleaNeurilemmomaMembrane ProteinsBrain NeoplasmsAnimalsMiceSTING ProteinProgrammed Cell Death 1 ReceptorDisease Models, AnimalHumansFemaleCombined Modality TherapyHearing LosscGAS-STING Signaling Pathway

Substances

Immune Checkpoint InhibitorsSTING ProteinProgrammed Cell Death 1 ReceptorMembrane ProteinsSting1 protein, mouse

Authors and institutions

  • Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Department of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

Funding

  • NIDCD NIH HHS
  • NINDS NIH HHS

Cite

APA

Yin, Z., Lu, S., Wu, L., Sun, Y., Blake, D. C., Chen, J., Landegger, L. D., Ho, W., Xiu, B., Jones, A. P., Muzikansky, A., Shih, H. A., Stankovic, K. M., Plotkin, S. R., & Xu, L. (2026). A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation. Theranostics. https://doi.org/10.7150/thno.123726

Vancouver

Yin Z, Lu S, Wu L, Sun Y, Blake DC, Chen J, et al. A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation. Theranostics. 2026. doi:10.7150/thno.123726

BibTeX
@article{Yin2026,
  author = {Yin, Zhenzhen and Lu, Simeng and Wu, Limeng and Sun, Yao and Blake, Day Caven and Chen, Jie and Landegger, Lukas D and Ho, William and Xiu, Bingyu and Jones, Adam P and Muzikansky, Alona and Shih, Helen A and Stankovic, Konstantina M and Plotkin, Scott R and Xu, Lei},
  title = {A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.123726}
}
Start for free →